Best Way to Get Rid of Man Boobs

The best way to get rid of man boobs depends entirely on what is causing them. True gynaecomastia, which involves glandular breast tissue growth driven by hormonal imbalance, requires a very different approach to pseudogynaecomastia, which is simply excess chest fat. Treatments range from lifestyle changes and addressing underlying medical conditions through to off-label medicines and surgery. This article explains how each type is identified, what the NHS offers, when surgery is appropriate, and what risks each treatment pathway carries.

What actually causes man boobs and does it matter for treatment?

The cause matters greatly: true gynaecomastia (glandular tissue) and pseudogynaecomastia (chest fat) respond to entirely different treatments, so accurate diagnosis by a GP is the essential first step.

The cause of enlarged male breast tissue matters greatly for treatment, because true gynaecomastia (glandular breast tissue growth) and pseudogynaecomastia (excess fatty tissue) respond to very different approaches. True gynaecomastia results from an imbalance between oestrogen and testosterone, causing the glandular tissue beneath the nipple to proliferate.^[1] Pseudogynaecomastia, by contrast, is simply the accumulation of adipose (fat) tissue in the chest area, without any glandular component.

Common causes of true gynaecomastia include:

• Puberty: Hormonal fluctuations during adolescence cause transient gynaecomastia in a significant proportion of boys, which often resolves spontaneously within one to two years.^[1]

• Medicines: Several drugs are associated with gynaecomastia, including spironolactone, cimetidine, some antipsychotics, anabolic steroids and certain antiretrovirals.^[1][5]

• Underlying conditions: Hypogonadism, hyperthyroidism, liver cirrhosis, chronic kidney disease and some testicular tumours can all disrupt the oestrogen-to-testosterone ratio.^[1]

• Recreational substances: Cannabis, alcohol and some illicit drugs have been associated with gynaecomastia, though the evidence for cannabis specifically is limited and inconsistent; it is listed as a possible contributing factor rather than a confirmed cause.

Distinguishing between the two types is clinically important. A GP will typically take a thorough history, examine the chest and testes, and may arrange blood tests including liver function, thyroid function, total testosterone, oestradiol, LH, FSH, prolactin and hCG. Testicular ultrasound may be considered where the history or examination raises concern. These investigations help to exclude an underlying hormonal or systemic cause.

It is also important to be aware that male breast cancer, though uncommon, can present as a breast lump. Features that warrant urgent assessment include a hard, irregular or eccentric lump (not centred directly beneath the nipple), nipple discharge, skin changes, or enlarged lymph nodes under the arm. If any of these features are present, a GP should be seen promptly; NICE guidance (NG12) sets out criteria for urgent two-week-wait referral for suspected breast cancer, which applies to men as well as women.

Fatty pseudogynaecomastia will not respond to hormonal treatments or to glandular excision surgery designed for true gynaecomastia, and vice versa. Identifying the root cause is therefore the essential first step before any treatment plan is considered.

Can you get rid of man boobs through exercise and diet alone?

Exercise and diet can effectively reduce pseudogynaecomastia but will not eliminate true gynaecomastia, as glandular breast tissue is not composed of fat and does not respond to calorie restriction.

Exercise and dietary changes can effectively reduce pseudogynaecomastia (fat-related chest enlargement), but they will not eliminate true gynaecomastia caused by glandular tissue growth. This distinction is fundamental: no amount of chest exercise or calorie restriction will shrink glandular breast tissue, because that tissue is not composed of fat. It is also worth noting that fat loss occurs throughout the body rather than in one targeted area; there is no evidence that chest-specific exercises reduce chest fat preferentially.

For pseudogynaecomastia, a sustained calorie deficit combined with regular cardiovascular exercise and resistance training can meaningfully reduce overall body fat, including in the chest area. Compound movements such as bench press, press-ups and rowing exercises help build the pectoral muscles beneath the fat, which can improve the chest's appearance as fat is lost. NICE guidance on weight management recommends a combination of dietary modification and increased physical activity as the cornerstone of any fat-reduction programme.

For true gynaecomastia, lifestyle changes play a supporting role rather than a curative one. Reducing alcohol intake, stopping anabolic steroid use, and avoiding cannabis (where this may be a contributing factor) may be helpful. Achieving a healthy body weight is also beneficial, as adipose tissue converts androgens to oestrogens (a process called peripheral aromatisation), so excess body fat can worsen hormonal imbalance.^[1] However, glandular tissue that has been present for more than 12 months is unlikely to resolve through lifestyle changes alone.^[1]

If lifestyle changes have been sustained for several months without meaningful improvement, or if the breast tissue is tender, firm, or located directly beneath the nipple, it is worth speaking to a GP. A clinical assessment can clarify whether glandular tissue is present and whether further investigation or treatment is warranted. Self-directed exercise programmes alone are unlikely to resolve confirmed gynaecomastia.

What medical treatments are available on the NHS for gynaecomastia?

NHS treatment focuses on addressing the underlying cause; off-label tamoxifen or anastrozole may be used under specialist supervision, but routine commissioning varies by Integrated Care Board.

NHS medical treatment for gynaecomastia is primarily directed at identifying and addressing the underlying cause, rather than prescribing medicines specifically to shrink breast tissue. Where a causative medicine is identified, the GP or specialist may review whether it can be stopped or substituted. Where an underlying condition such as hypogonadism or hyperthyroidism is found, treating that condition may lead to gradual resolution of the gynaecomastia.

Pharmacological treatments such as tamoxifen (a selective oestrogen receptor modulator) are sometimes used off-label in specialist settings for painful or persistent gynaecomastia, particularly in adolescents where surgery is not yet appropriate.^[3][9] Anastrozole (an aromatase inhibitor) has also been used off-label in this context, though the evidence supporting its benefit is more limited than for tamoxifen.^[4][9] Neither medicine is routinely commissioned for gynaecomastia across the NHS; availability varies by Integrated Care Board (ICB), and their use is guided by an endocrinologist or breast specialist rather than a GP. Both should only be used under specialist supervision, and patients should discuss the potential benefits and risks with their prescriber.

NHS referral pathways typically involve:

• GP assessment to exclude secondary causes and review current medicines.

• Referral to endocrinology or breast surgery if the gynaecomastia is persistent (generally beyond 12 months), painful, or associated with abnormal blood results.

• Urgent referral if features suggest possible breast cancer (see the first section above); NICE NG12 sets out the criteria for urgent two-week-wait referral, which applies to men.

• Psychological support where body image distress is significant, which a GP can facilitate via NHS Talking Therapies (the current name for what was previously called IAPT in England; equivalent services exist in Scotland, Wales and Northern Ireland).^[13]

NHS surgical treatment for gynaecomastia is available in some areas but is subject to local ICB commissioning decisions, and eligibility criteria vary. Patients should discuss their individual circumstances with their GP, who can advise on what is available locally.

When is surgery the right option and what does it involve?

Surgery is most appropriate when true gynaecomastia has persisted beyond 12 months and become fibrotic; glandular excision or liposuction is performed, often as a day-case procedure under general anaesthetic.

Surgery is the most definitive treatment for true gynaecomastia that has not resolved with lifestyle changes or treatment of an underlying cause, particularly when the condition has been present for more than 12 months and the glandular tissue has become fibrotic. At that stage, the tissue is unlikely to regress spontaneously or respond to medical management, and surgical removal offers the most reliable long-term outcome.

Two main surgical approaches are used:

• Liposuction: Suitable where the enlargement is predominantly fatty (pseudogynaecomastia). A small cannula is inserted through a minor incision to remove fat, leaving minimal scarring. It does not remove glandular tissue effectively on its own.

• Glandular excision (mastectomy): The glandular tissue beneath the nipple is surgically removed through a small incision, usually at the edge of the areola. This is the standard approach for true gynaecomastia and can be combined with liposuction where both fat and glandular tissue are present.

Surgery is typically performed under general anaesthetic, often as a day-case procedure, though the specific approach, anaesthetic method and recovery plan will vary depending on the surgeon and the extent of the procedure. Recovery generally involves wearing a compression garment for several weeks, avoiding strenuous activity for around four to six weeks, and attending follow-up appointments to monitor healing. Individual advice from the operating surgeon takes precedence over any general guidance.

Preoperative optimisation is important. Surgeons will usually advise achieving a stable body weight before the procedure, stopping smoking, and ensuring any underlying hormonal condition is well managed, as these factors affect both surgical risk and the likelihood of recurrence.

On the NHS, surgery for gynaecomastia is generally considered only where the condition causes significant physical symptoms (such as persistent pain or skin irritation) or severe psychological distress, and where conservative measures have been exhausted. Eligibility is determined locally by the relevant ICB. Privately, surgery is more readily accessible; a consultation with a GMC-registered plastic or breast surgeon is the appropriate starting point, and patients may also wish to check whether their surgeon is a member of BAAPS (British Association of Aesthetic Plastic Surgeons) or BAPRAS (British Association of Plastic, Reconstructive and Aesthetic Surgeons).

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, for those whose chest concerns are related to excess body weight rather than glandular tissue.

Are there any risks or side effects from gynaecomastia treatments?

Surgical risks include asymmetry, scarring, haematoma and recurrence; tamoxifen carries a small risk of thromboembolic events, and anastrozole can reduce bone mineral density with prolonged use.

All treatments for gynaecomastia carry potential risks, and understanding these helps patients make informed decisions in discussion with their clinical team. The nature of the risks depends on the treatment pathway chosen.

Surgical risks include those common to any procedure under general anaesthetic (such as infection, bleeding and adverse reactions to anaesthesia), as well as procedure-specific complications:

• Asymmetry or contour irregularities

• Changes in nipple sensation (temporary or permanent)

• Scarring, which is usually minimal but can be more pronounced in some individuals

• Haematoma (blood pooling beneath the skin) or seroma (fluid accumulation)

• Recurrence, particularly if the underlying hormonal cause has not been addressed

Medical treatment risks depend on the agent used. Off-label use of tamoxifen is associated with hot flushes, mood changes and, rarely, thromboembolic events such as deep vein thrombosis or pulmonary embolism; patients should seek urgent medical attention if they develop calf pain, leg swelling or breathlessness.^[3][11] Anastrozole can affect bone mineral density with prolonged use.^[4][7] These medicines should only be used under specialist supervision; the BNF provides full details of cautions and adverse effects for both agents.

Lifestyle interventions carry minimal direct risk, though rapid weight loss can occasionally worsen the appearance of gynaecomastia temporarily by reducing surrounding fat before the skin adapts.

Patients should contact their GP promptly if they notice:

• A rapidly enlarging or painful lump beneath the nipple

• Nipple discharge

• Skin changes over the breast area

• Fever, increasing redness or spreading warmth around a surgical wound, which may indicate infection

• Symptoms suggesting an underlying systemic condition

Suspected side effects from any prescribed medicine can be reported to the MHRA via the Yellow Card scheme at yellowcard.^[12][6]mhra.gov.uk. For urgent concerns following surgery, contact NHS 111 for advice, or attend A&E if there is heavy bleeding, signs of severe infection, or breathing difficulties.

Scientific References

1. Breast reduction (male).
2. Suspected cancer: recognition and referral (NG12).
3. Tamoxifen | Drugs – BNF – NICE.
4. Anastrozole | Drugs – BNF – NICE.
5. Spironolactone | Drugs – BNF – NICE.
6. Adverse reactions to drugs | Medicines guidance – BNF – NICE.
7. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial.
8. Effect of anastrozole on bone mineral density: 5-year results from the ATAC trial.
9. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy.
10. Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review.
11. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism.
12. The Yellow Card scheme: guidance for healthcare professionals, patients and the public.
13. Talking therapies.

Frequently Asked Questions